”type”:”clinical-trial”,”attrs”:”text”:”NCT01226485″,”term_id”:”NCT01226485″NCT01226485Phase 1Advanced cancerTaladegib The utmost tolerable dose was 400 mg [87]

”type”:”clinical-trial”,”attrs”:”text”:”NCT01226485″,”term_id”:”NCT01226485″NCT01226485Phase 1Advanced cancerTaladegib The utmost tolerable dose was 400 mg [87].”type”:”clinical-trial”,”attrs”:”text”:”NCT01546038″,”term_id”:”NCT01546038″NCT01546038Phase 1/2Apretty myeloid leukemiaHigh-risk myelodysplastic syndromesA: Glasdegib + low-dose ARA-CB: Glasdegib + decitabineC: Glasdegib + daunorubicin + cytarabine Zero dose-limiting toxicities (DLT) were seen in hands A and B; 1

Inhibition of intracellular calcium release as well as blockade of calcium-dependent PKC isoforms or calcium/calmodulin-dependent protein kinase II (CaMKII) significantly reduced the PACAP-induced RAGE shedding

Inhibition of intracellular calcium release as well as blockade of calcium-dependent PKC isoforms or calcium/calmodulin-dependent protein kinase II (CaMKII) significantly reduced the PACAP-induced RAGE shedding. Ca2+ signaling, PKC/PKCI, CaMKII, PI3 kinases and MAP kinases to be involved in PAC1 receptor-induced

Data on the transient inactivation of c-MYC indicate selective effects on cancer cells,18 but exactly why cancer cells are more sensitive to these effects than normal regenerative tissues is not clear

Data on the transient inactivation of c-MYC indicate selective effects on cancer cells,18 but exactly why cancer cells are more sensitive to these effects than normal regenerative tissues is not clear. How broadly relevant is blocking translation in cancer? Translation